Supplemental Figure 1







Supplemental Figure 2. Human sCTLA-4 immunoassay calibration curves. (A) Linear detection is observed for 2-fold serial dilutions of recombinant sCTLA-4 secreted into the culture medium of HeLa transfectants (sCTLA-4/HeLa) as measured by the sCTLA-4 immunoassay (closed triangles). Tm-CTLA-4 protein from transfected HeLa cell-derived detergent lysates (1 x 10⁴ and 5 x 10³ cells) is not detected in this assay format (open squares); recombinant secreted sCTLA-4 protein did not bind to an isotype matched IgG_{2ak} antibody (open triangles). In data not shown, binding of the CTLA-4/Fc fusion protein was also not detected. (B, C) Quantitation of secreted recombinant sCTLA-4 calculated in a pan-CTLA-4 immunoassay (capture: BN13 mAb, detection: biotinylated 14D3 mAb) using serial dilutions of CTLA-4/Fc fusion protein for the standard curve. Detergent lysates from Tm-CTLA-4/HeLa cells (1 x 10⁴ and 5 x 10³ cells) served as positive controls. Isotype-matched IgG_{2ak} antibody as the capture reagent was used as a control for non-specific binding, such as observed with heterophilic antibodies. (D) Limit of detection of sCTLA-4 protein secreted into culture supernatant of HeLa cell transfectants analyzed by Western blot. Serial dilutions of scTLA-4 protein detected by Western blot is approximately 9 pg per lane (equating to loading a maximum of 37 microliters per lane of a 243 pg/ml solution). All experiments are representative of at least three independent observations.

Supplemental Figure 3





Supplemental Figure 3. Assessment of sCTLA-4 in serum samples from GD and T1D patients and control cohorts. Serum samples from 18 GD patients and 15 age- and sex-matched healthy controls (A, B) and 14 T1D patients and 14 age- and sex-matched healthy controls (C, D) diluted 1/20 and 1/40 were tested with the sCTLA-4-specific immunoassay and the pan-CTLA-4 immunoassay (filled columns). Each sample was also tested for binding to an isotype-matched mouse IgG_{2ak} capture antibody (open columns). Columns are the mean of duplicate measurements. Samples in each of the disease and control cohorts are labelled (P1 through P18, for example in Supplemental 3A) based on their ranking from the lowest to highest europium counts in the sCTLA-4 assay as tested at a 1/20 dilution (Supplemental 3A and 3C, first and third graphs) to facilitate comparison with the pan-CTLA-4 assay results where the lowest to highest europium counts are also presented.

Supplemental Figure 4



Supplemental Figure 4. Analysis of serum-derived microvesicles. Microvesicles were isolated from sera of T1D patients and healthy volunteers (HV) by sequential ultracentrifugation and analyzed by Western blot using anti-CD63 and anti-CD3 ζ mAbs. Western blot gel is representative of at least four independent experiments.